Drug Pipeline Success: Positive clinical trial results and regulatory approvals for new drugs typically boost GSK's stock price, reflecting future revenue potential.

Competition: Intense competition from generic and biosimilar drugs can erode market share and pressure pricing, negatively affecting GSK's revenues and stock value.

Economic Conditions: Economic downturns can impact healthcare spending, potentially reducing demand for GSK's products and affecting its financial performance.

Regulatory Changes: Changes in healthcare regulations, such as pricing controls or drug approval processes, can significantly influence GSK's profitability and stock price.

Patent Expirations: When patents on key drugs expire, GSK faces competition from cheaper generics, which reduces revenue and stock value.

Mergers and Acquisitions: Strategic acquisitions or mergers can alter GSK's market position and future prospects, impacting investor sentiment and stock price.

Dividend Policy: GSK's dividend payouts can influence investor demand for its stock, as a higher dividend yield may attract income-seeking investors.

Global Health Crises: Pandemics or outbreaks of infectious diseases can create both opportunities and challenges for GSK, affecting its research priorities and product demand.

Research and Development Spending: The level of investment GSK makes in R&D can signal its commitment to innovation and future growth, potentially influencing stock price.

Litigation and Legal Issues: Lawsuits or legal challenges related to GSK's products or business practices can create uncertainty and negatively impact investor confidence.